Compare NAC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAC | ANIP |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | NAC | ANIP |
|---|---|---|
| Price | $11.78 | $85.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $107.33 |
| AVG Volume (30 Days) | 307.3K | ★ 525.1K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | ★ $826,880,000.00 |
| Revenue This Year | N/A | $44.37 |
| Revenue Next Year | N/A | $9.83 |
| P/E Ratio | ★ N/A | $51.06 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $9.32 | $54.10 |
| 52 Week High | $11.21 | $99.50 |
| Indicator | NAC | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 58.46 |
| Support Level | $11.75 | $83.03 |
| Resistance Level | $11.87 | $87.07 |
| Average True Range (ATR) | 0.08 | 3.49 |
| MACD | -0.02 | 0.80 |
| Stochastic Oscillator | 7.46 | 89.93 |
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.